Trial Profile

Safety and efficacy of Universal Infuenza Vaccine in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Universal influenza vaccine Versatope Therapeutics (Primary)
Indications Influenza virus infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Jun 2020 According to an Intravacc media release, Intravacc and Versatope have signed a research service agreement under which Intravacc will provide its services to Versatope in bringing VT-105 towards first clinical trials.
10 Oct 2019 New trial record
25 Sep 2019 According to a Versatope Therapeutics media release, NIAID funding will support human clinical studies to demonstrate safety and tolerability in healthy volunteers.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com